PTC Therapeutics, Inc. (BH3)

Overview

PTC Therapeutics, Inc. is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of novel medicines for patients with rare disorders, both within the United States and internationally. Since its establishment in 1998, the company has been committed to addressing the needs of patients who suffer from rare diseases by leveraging innovative science and groundbreaking therapies. With its headquarters in South Plainfield, New Jersey, PTC Therapeutics has forged strategic collaborations with renowned entities such as F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. to expand its influence and reach in the rare disease space.

Products and Services

• Translarna and Emflaza

  These products are specifically developed for the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. Translarna and Emflaza aim to improve muscle strength and function in patients suffering from DMD.

• Upstaza

  Upstaza is designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare central nervous system disorder. This treatment targets the underlying cause of the disorder, aiming to improve motor function and quality of life for affected individuals.

• Tegsedi and Waylivra

  These therapies are tailored for the treatment of rare diseases, with Tegsedi being approved for patients with hereditary TTR-mediated amyloidosis (hATTR) and Waylivra designated for familial chylomicronemia syndrome (FCS). They focus on reducing disease progression and alleviating symptoms.

• Evrysdi

  Evrysdi is an oral treatment for spinal muscular atrophy (SMA) in adults and children, designed to increase the production of the survival motor neuron (SMN) protein, critical for muscle movement and strength.

• Sepiapterin for Phenylketonuria

  This development stage product aims to treat phenylketonuria (PKU), a genetic disorder that increases the levels of phenylalanine in the blood, potentially leading to serious health problems.

• PTC518 Splicing Platform for Huntington's Disease

  A cutting-edge development focused on Huntington's disease, this platform is designed to modulate splicing as a novel approach to treat this genetic disorder affecting the brain.

• Ferroptosis and Inflammation Platforms

  These platforms include vatiquinone, intended for the treatment of Friedreich ataxia, and utreloxastat, aimed at combating amyotrophic lateral sclerosis (ALS). Both are part of PTC's efforts to target and treat neurodegenerative and rare diseases through innovative mechanisms.